Akebia Therapeutics, Inc. Business Finance Contracts & Agreements
39 Contracts & Agreements
- Assignment Agreements (1 contract)
- Credit Agreements (2)
- Exchange Agreements (1)
- Guaranty Agreements (1)
- Investment Agreements (2)
- Investor Rights Agreements (5)
- Loan Agreements (5)
- Note Agreements (5)
- Registration Rights Agreements (1)
- Release Agreements (1)
- Security Agreements (1)
- Stock Agreements (6)
- Underwriting Agreements (6)
- Warrant Agreements (2)
- Warrant Agreement dated January 29, 2024 by and between the Company and Kreos Capital VII Aggregator SCSp (Filed With SEC on March 14, 2024)
- Agreement for the Provision of a Loan Facility dated January 29, 2024 between the Company and Kreos Capital VII (UK) Limited (Filed With SEC on March 14, 2024)
- Fourth Amendment to Loan Agreement dated as of October 31, 2023, by and among the Company, BioPharma Credit PLC, BPCR Limted Partnership, and BioPharma Credit Investments V... (Filed With SEC on March 14, 2024)
- Form of Officer Inducement Award Stock Option (Filed With SEC on March 14, 2024)
- Form of Warrant (Filed With SEC on March 14, 2024)
- Third Amendment to Loan Agreement, dated as of June 30, 2023, by and among the Company, Biopharma Credit plc, B (Filed With SEC on August 28, 2023)
- Form of Stock Appreciation Rights Award Agreement for officers (Filed With SEC on May 8, 2023)
- Second Amendment and Waiver, dated July 15, 2022, by and among the Company, Biopharma Credit plc, BCPR Limited Partnership and Biopharma Credit Investments V (Master) LP (Filed With SEC on August 4, 2022)
- Form of Officer Restricted Stock Unit Award Agreement (Filed With SEC on August 4, 2022)
- Assignment and Assumption Agreement, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc (Filed With SEC on March 1, 2022)
- Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated February 18, 2022 (Filed With SEC on March 1, 2022)
- Underwriting Agreement, dated May 11, 2020, by and among Akebia Therapeutics, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the several... (Filed With SEC on May 12, 2020)
- Loan Agreement, dated November 11, 2019, by and among the Company, Keryx Biopharmaceuticals, Inc., Biopharma Credit plc and Biopharma Credit Investments V (Master) LP (Filed With SEC on March 12, 2020)
- Guaranty and Security Agreement, dated November 25, 2019, by and between the Company, Keryx Biopharmaceuticals, Inc. and Biopharma Credit plc (Filed With SEC on March 12, 2020)
- Unconditional Guaranty, dates as August 7, 2019, by and between Akebia Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)
- Security Agreement, dated as of August 7, 2019, by and between Akebia Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)
- Waiver and First Amendment to Loan Security and Security Agreement, dated as of July 31, 2019, by and between Keryx Biopharmaceuticals, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)
- Keryx Biopharmaceuticals, Inc. Director Non-Statutory Stock Option Award Terms and Conditions under the Third Amended and Restated Directors Equity Compensation Plan (Filed With SEC on March 26, 2019)
- Registration Rights Agreement, dated December 12, 2018, by and between Akebia Therapeutics, Inc. and Baupost Group Securities, L.L.C (Filed With SEC on December 13, 2018)
- Notes Conversion Agreement, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C (Filed With SEC on June 28, 2018)
- Underwriting Agreement, dated March 22, 2018, between Akebia Therapeutics, Inc. and Morgan Stanley & Co. LLC, as underwriter (Filed With SEC on March 26, 2018)
- Amendment No. 1 to Fourth Amended and Restated Investors Rights Agreement, dated June 28, 2017 (Filed With SEC on March 12, 2018)
- Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated May 12, 2017 (Filed With SEC on August 8, 2017)
- 4,000,000 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on June 29, 2017)
- 7,250,000 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on January 12, 2016)
- AKEBIA THERAPEUTICS, INC. Shares of Common Stock (par value$0.00001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on August 11, 2015)
- 7,272,727 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on April 17, 2015)
- FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on March 4, 2015)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 4, 2014)
- AKEBIA THERAPEUTICS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on March 4, 2014)
- FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on March 4, 2014)
- Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on March 4, 2014)
- FORGIVENESS AND RELEASE AGREEMENT (Filed With SEC on February 14, 2014)
- Akebia Therapeutics, Inc. AMENDED AND RESTATED PARTIAL RECOURSE PROMISSORY NOTE (Filed With SEC on February 14, 2014)
- Akebia Therapeutics, Inc. AMENDED AND RESTATED PARTIAL RECOURSE PROMISSORY NOTE (Filed With SEC on February 14, 2014)
- Akebia Therapeutics, Inc. AMENDED AND RESTATED PARTIAL RECOURSE PROMISSORY NOTE (Filed With SEC on February 14, 2014)
- Akebia Therapeutics, Inc. AMENDED AND RESTATED PARTIAL RECOURSE PROMISSORY NOTE (Filed With SEC on February 14, 2014)
- AMENDMENT NO. 1 TO THETHIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on February 14, 2014)
- THIRDAMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on February 14, 2014)
